This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Suzuki, K. Search for Related Content PubMed PubMed Citation Articles by Suzuki, K. Social Bookmarking                   What's this?

Globoid Cell Leukodystrophy (Krabbe's Disease): Update

Neuroscience Center and the Departments of Neurology and Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, kuni.suzuki{at}attglobal.net.

The classic globoid cell leukodystrophy (Krabbe's disease) is caused by genetic defects in a lysosomal enzyme, galactosylceramidase. It is one of the two classic genetic leukodystrophies, together with metachromatic leukodystrophy. The mode of inheritance is autosomal recessive. Typically, the disease occurs among infants and takes a rapidly fatal course, but rarer late-onset forms also exist. Clinical manifestations are exclusively neurologic with prominent white-matter signs. The pathology is unique, consisting of a rapid and nearly complete disappearance of myelin and myelin-forming cells— the oligodendrocytes in the central nervous system and the Schwann cells in the peripheral nervous system, reactive astroytic gliosis, and infiltration of the unique and often multinucleated macrophages ("globoid cells") that contain strongly periodic acid—Schiff (PAS)—positive materials. A normally insignificant but highly cytotoxic metabolite, galactosylsphingosine (psychosine), is also a substrate of galactosylceramidase and is considered to play a critical role in the pathogenesis. The galactosylceramidase gene has been cloned, and a large number of disease-causing mutations have been identified. Equivalent genetic galactosylceramidase deficiency occurs in several mammalian species, such as mouse, dog, and monkey. Recently, deficiency of one of the sphingolipid activator proteins, saposin A, was demonstrated to cause a late-onset, slowly progressive globoid cell leukodystrophy at least in the mouse, with all of the phenotypic consequences of impaired degradation of galactosylceramidase substrates. Human globoid cell leukodystrophy owing to saposin A deficiency might be anticipated and should be suspected in human patients with a late-onset leukodystrophy with normal galactosylceramidase activity when other possibilities are also excluded. The only serious attempt at treating human patients is bone marrow transplantation, which can provide significant alleviation of symptoms, particularly in those patients with later-onset, more slowly progressive globoid cell leukodystrophy. (J Child Neurol 2003;18:595—603).

Journal of Child Neurology, Vol. 18, No. 9, 595-603 (2003)
DOI: 10.1177/08830738030180090201


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. M. Provenzale, S. Peddi, J. Kurtzberg, M. D. Poe, S. Mukundan, and M. Escolar Correlation of Neurodevelopmental Features and MRI Findings in Infantile Krabbe's Disease Am. J. Roentgenol., January 1, 2009; 192(1): 59 - 65. [Abstract] [Full Text] [PDF]

				S. A. Goldman, S. Schanz, and M. S. Windrem Stem cell-based strategies for treating pediatric disorders of myelin Hum. Mol. Genet., April 15, 2008; 17(R1): R76 - R83. [Abstract] [Full Text] [PDF]

				J. T. Borda, X. Alvarez, M. Mohan, M. S. Ratterree, K. Phillippi-Falkenstein, A. A. Lackner, and B. A. Bunnell Clinical and Immunopathologic Alterations in Rhesus Macaques Affected with Globoid Cell Leukodystrophy Am. J. Pathol., January 1, 2008; 172(1): 98 - 111. [Abstract] [Full Text] [PDF]

				Z. A. Siddiqi, D. B. Sanders, and J. M. Massey Peripheral neuropathy in Krabbe disease: effect of hematopoietic stem cell transplantation. Neurology, July 25, 2006; 67(2): 268 - 272. [Abstract] [Full Text] [PDF]

				I. Sahai, H. Baris, V. Kimonis, and H. L. Levy Krabbe Disease: Severe Neonatal Presentation With a Family History of Multiple Sclerosis J Child Neurol, October 1, 2005; 20(10): 826 - 828. [Abstract] [PDF]

				P. McGraw, L. Liang, M. Escolar, S. Mukundan, J. Kurtzberg, and J. M. Provenzale Krabbe Disease Treated with Hematopoietic Stem Cell Transplantation: Serial Assessment of Anisotropy Measurements--Initial Experience Radiology, July 1, 2005; 236(1): 221 - 230. [Abstract] [Full Text] [PDF]